{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:34:04Z","timestamp":1781825644229,"version":"3.54.5"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T00:00:00Z","timestamp":1465516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/eye.2016.94","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T13:28:04Z","timestamp":1465565284000},"page":"1293-1309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Revisiting the role of erythropoietin for treatment of ocular disorders"],"prefix":"10.1038","volume":"30","author":[{"given":"S L","family":"Shirley Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S N","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Munisvaradass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E H","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M L C","family":"Bastion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Y","family":"Then","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P L","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,10]]},"reference":[{"key":"BFeye201694_CR1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bcp.2011.06.045","volume":"82","author":"S Chateauvieux","year":"2011","unstructured":"Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M . Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 2011; 82, pp 1291\u20131303.","journal-title":"Biochem Pharmacol"},{"key":"BFeye201694_CR2","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0406491101","volume":"101","author":"M Brines","year":"2004","unstructured":"Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907\u201314912.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye201694_CR3","first-page":"307","volume":"20","author":"C Caprara","year":"2014","unstructured":"Caprara C, Britschgi C, Samardzija M, Grimm C . The erythropoietin receptor is not required for the development, function, and aging of rods and cells in the retinal periphery. Mol Vis 2014; 20: 307\u2013324.","journal-title":"Mol Vis"},{"key":"BFeye201694_CR4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2337\/dc07-2075","volume":"31","author":"M Garc\u00eda-Ram\u00edrez","year":"2008","unstructured":"Garc\u00eda-Ram\u00edrez M, Hern\u00e1ndez C, Sim\u00f3 R . Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects. Diabetes Care 2008; 31: 1189\u20131194.","journal-title":"Diabetes Care"},{"key":"BFeye201694_CR5","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ymthe.2004.07.027","volume":"10","author":"TS Rex","year":"2004","unstructured":"Rex TS, Allocca M, Domenici L, Surace EM, Maguire AM, Lyubarsky A et al. Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Mol Ther 2004; 10: 855\u2013861.","journal-title":"Mol Ther"},{"key":"BFeye201694_CR6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1203\/00006450-199804001-00243","volume":"43","author":"MK Philbin","year":"1998","unstructured":"Philbin MK, Ballweg DD, Tsakiri S, Robinson L, Posz N, Gray L et al. Hospital cost savings and physiologic benefit of developmentally supportive care for very low birth weight newborns 222. Pediatr Res 1998; 43: 40\u201340.","journal-title":"Pediatr Res"},{"key":"BFeye201694_CR7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1756-0500-2-234","volume":"2","author":"SS Shah","year":"2009","unstructured":"Shah SS, Tsang SH, Mahajan VB . Erythropoetin receptor expression in the human diabetic retina. BMC Res Notes 2009; 2: 234.","journal-title":"BMC Res Notes"},{"key":"BFeye201694_CR8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nm723","volume":"8","author":"C Grimm","year":"2002","unstructured":"Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002; 8: 718\u2013724.","journal-title":"Nat Med"},{"key":"BFeye201694_CR9","first-page":"526","volume":"118","author":"J Chen","year":"2008","unstructured":"Chen J, Connor KM, Aderman CM, Smith LEH . Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008; 118: 526\u2013533.","journal-title":"J Clin Invest"},{"key":"BFeye201694_CR10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.exer.2009.06.017","volume":"89","author":"TS Rex","year":"2009","unstructured":"Rex TS, Wong Y, Kodali K, Merry S . Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Exp Eye Res 2009; 89: 735\u2013740.","journal-title":"Exp Eye Res"},{"key":"BFeye201694_CR11","first-page":"5896","volume":"49","author":"A Szabo","year":"2008","unstructured":"Szabo A, Vegvari D, Deak G, Lukats A, Berta AI, Szel A . The expression of erythropoietin and its receptor in the developing rat retina. Invest Ophthalmol Vis Sci 2008; 49: 5896.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR12","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1073\/pnas.152321399","volume":"99","author":"AK Junk","year":"2002","unstructured":"Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002; 99: 10659\u201310664.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye201694_CR13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1203\/PDR.0b013e318165b8d1","volume":"63","author":"S Patel","year":"2008","unstructured":"Patel S, Rowe MJ, Winters SA, Ohls RK . Elevated erythropoietin mRNA and protein concentrations in the developing human eye. Pediatr Res 2008; 63: 394\u2013397.","journal-title":"Pediatr Res"},{"key":"BFeye201694_CR14","first-page":"3078","volume":"49","author":"L Wu","year":"2008","unstructured":"Wu L, Chang S, Chen Y, Xia Q, Forbes M, Tsai JC . Erythropoietin receptor plays a role in the cell differentiation of retina and lens during eye development. Invest Ophthalmol Vis Sci 2008; 49: 3078.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR15","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/hmg\/ddr115","volume":"20","author":"P Colella","year":"2011","unstructured":"Colella P, Iodice C, Di Vicino U, Annunziata I, Surace EM, Auricchio A . Non-erythropoietic erythropoietin derivatives protect from light-induced and genetic photoreceptor degeneration. Hum Mol Genet 2011; 20: 2251\u20132262.","journal-title":"Hum Mol Genet"},{"key":"BFeye201694_CR16","first-page":"31","volume":"5","author":"WS Bond","year":"2014","unstructured":"Bond WS, Rex TS . Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes, and microglia. Front Immunol 2014; 5: 31\u201335.","journal-title":"Front Immunol"},{"key":"BFeye201694_CR17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","volume":"39","author":"J Li","year":"2006","unstructured":"Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006; 39: 754\u2013766.","journal-title":"Bone"},{"key":"BFeye201694_CR18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.2741\/1982","volume":"11","author":"RU De Iongh","year":"2006","unstructured":"De Iongh RU, Abud HE, Hime GR . 2442 WNT\/Frizzled signaling in eye development and disease. Front Biosci 2006; 11: 2442\u20132464.","journal-title":"Front Biosci"},{"key":"BFeye201694_CR19","doi-asserted-by":"crossref","first-page":"e55291","DOI":"10.1371\/journal.pone.0055291","volume":"8","author":"ZY Chang","year":"2013","unstructured":"Chang ZY, Yeh MK, Chiang CH, Chen YH, Lu DW . Erythropoietin protects adult retinal ganglion cells against NMDA-, trophic factor withdrawal-, and TNF-\u03b1-induced damage. PLoS One 2013; 8: e55291.","journal-title":"PLoS One"},{"key":"BFeye201694_CR20","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/jnr.22046","volume":"87","author":"H Chung","year":"2009","unstructured":"Chung H, Lee H, Lamoke F, Hrushesky WJM, Wood PA, Jahng WJ . Neuroprotective role of erythropoietin by antiapoptosis in the retina. J Neurosci Res 2009; 87: 2365\u20132374.","journal-title":"J Neurosci Res"},{"key":"BFeye201694_CR21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1096\/fj.04-2493fje","volume":"19","author":"U Kilic","year":"2005","unstructured":"Kilic U, Kilic E, Soliz J, Bassetti CI, Gassmann M, Hermann DM . Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1\/-2. FASEB J 2005; 19: 249\u2013251.","journal-title":"FASEB J"},{"key":"BFeye201694_CR22","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.freeradbiomed.2008.11.027","volume":"46","author":"Z Wang","year":"2009","unstructured":"Wang Z, Shen L, Tu L, Hu D, Liu G-Y, Zhou Z et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic Biol Med 2009; 46: 1032\u20131041.","journal-title":"Free Radic Biol Med"},{"key":"BFeye201694_CR23","first-page":"3695","volume":"10","author":"H Zhang","year":"2013","unstructured":"Zhang H, Gong Y, Wu X, Shi Y, Yin L, Qiu Y . Erythropoietin protects the retinal pigment epithelial barrier against non-lethal H 2 O 2 -induced hyperpermeability. African J Biotechnol 2013; 10: 3695\u20133703.","journal-title":"African J Biotechnol"},{"key":"BFeye201694_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/156720206778018758","volume":"3","author":"F Li","year":"2006","unstructured":"Li F, Chong ZZ, Maiese K . Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res 2006; 3: 187\u2013201.","journal-title":"Curr Neurovasc Res"},{"key":"BFeye201694_CR25","first-page":"656","volume":"44","author":"M-H Kim","year":"2010","unstructured":"Kim M-H, Cho G-W, Huh Y-M, Kim SH, Koh S-H, Huh Y-M et al. Transduction of human EPO into human bone marrow mesenchymal stromal cells synergistically enhances cell-protective and migratory effects. Mol Biol (Mosk) 2010; 44: 656\u2013663.","journal-title":"Mol Biol (Mosk)"},{"key":"BFeye201694_CR26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0006-8993(02)03239-0","volume":"952","author":"D Agnello","year":"2002","unstructured":"Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952: 128\u2013134.","journal-title":"Brain Res"},{"key":"BFeye201694_CR27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/IAI.00929-13","volume":"82","author":"X Wei","year":"2014","unstructured":"Wei X, Li Y, Sun X, Zhu X, Feng Y, Liu J et al. Erythropoietin protects against murine cerebral malaria through actions on host cellular immunity. Infect Immun 2014; 82: 165\u2013173.","journal-title":"Infect Immun"},{"key":"BFeye201694_CR28","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20021067","volume":"198","author":"P Villa","year":"2003","unstructured":"Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A et al. Erythropoietin Selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971\u2013975.","journal-title":"J Exp Med"},{"key":"BFeye201694_CR29","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1523\/JNEUROSCI.1288-04.2004","volume":"24","author":"C Grimm","year":"2004","unstructured":"Grimm C . Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration. J Neurosci 2004; 24: 5651\u20135658.","journal-title":"J Neurosci"},{"key":"BFeye201694_CR30","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1038\/sj.cdd.4401504","volume":"11","author":"MB S\u00e4ttler (n\u00e9e Hobom)","year":"2004","unstructured":"S\u00e4ttler (n\u00e9e Hobom) MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, B\u00e4hr M et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11: S181\u2013S192.","journal-title":"Cell Death Differ"},{"key":"BFeye201694_CR31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jneuroim.2005.10.016","volume":"172","author":"C Savino","year":"2006","unstructured":"Savino C, Pedotti R, Baggi F, Ubiali F, Gallo B, Nava S et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 2006; 172: 27\u201337.","journal-title":"J Neuroimmunol"},{"key":"BFeye201694_CR32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/eye.2011.254","volume":"26","author":"Z Xie","year":"2012","unstructured":"Xie Z, Chen F, Wu X, Zhuang C, Zhu J, Wang J et al. Safety and efficacy of intravitreal injection of recombinant erythropoietin for protection of photoreceptor cells in a rat model of retinal detachment. Eye (Lond) 2012; 26: 144\u2013152.","journal-title":"Eye (Lond)"},{"key":"BFeye201694_CR33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.exer.2006.01.016","volume":"83","author":"O Arjamaa","year":"2006","unstructured":"Arjamaa O, Nikinmaa M . Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006; 83: 473\u2013483.","journal-title":"Exp Eye Res"},{"key":"BFeye201694_CR34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrrheum.2012.36","volume":"8","author":"C Maes","year":"2012","unstructured":"Maes C, Carmeliet G, Schipani E . Hypoxia-driven pathways in bone development, regeneration and disease. Nat Rev Rheumatol 2012; 8: 358\u2013366.","journal-title":"Nat Rev Rheumatol"},{"key":"BFeye201694_CR35","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1167\/iovs.07-0721","volume":"49","author":"J Zhang","year":"2008","unstructured":"Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008; 49: 732\u2013742.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/1357-6283.101509","volume":"23","author":"NM Lai","year":"2010","unstructured":"Lai NM, Nalliah S . Information-seeking practices of senior medical students: the impact of an evidence-based medicine training programme. Educ Health (Abingdon) 2010; 23: 151.","journal-title":"Educ Health (Abingdon)"},{"key":"BFeye201694_CR37","doi-asserted-by":"crossref","first-page":"e104759","DOI":"10.1371\/journal.pone.0104759","volume":"9","author":"W Shen","year":"2014","unstructured":"Shen W, Chung SH, Irhimeh MR, Li S, Lee SR, Gillies MC . Systemic administration of erythropoietin inhibits retinopathy in RCS rats. PLoS One 2014; 9: e104759.","journal-title":"PLoS One"},{"key":"BFeye201694_CR38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/0006-291X(89)91528-3","volume":"164","author":"JF Bazan","year":"1989","unstructured":"Bazan JF . A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor \u03b2-chain. Biochem Biophys Res Commun 1989; 164: 788\u2013795.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFeye201694_CR39","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/jcp.22678","volume":"226","author":"KH Su","year":"2011","unstructured":"Su KH, Shyue SK, Kou YR, Ching LC, Chiang AN, Yu YB et al. Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 2011; 226: 3330\u20133339.","journal-title":"J Cell Physiol"},{"key":"BFeye201694_CR40","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.2337\/diabetes.54.suppl_2.S114","volume":"54","author":"OP Kristiansen","year":"2005","unstructured":"Kristiansen OP, Mandrup-Poulsen T . Interleukin-6 and diabetes: The good, the bad, or the indifferent? Diabetes 2005; 54: S114\u2013S124.","journal-title":"Diabetes"},{"key":"BFeye201694_CR41","doi-asserted-by":"crossref","first-page":"8145","DOI":"10.1128\/JVI.73.10.8145-8151.1999","volume":"73","author":"Ra LeBlanc","year":"1999","unstructured":"LeBlanc R a, Pesnicak L, Cabral ES, Godleski M, Straus SE . Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes simplex virus type 1 in IL-6 knockout mice. J Virol 1999; 73: 8145\u20138151.","journal-title":"J Virol"},{"key":"BFeye201694_CR42","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.8511589","volume":"260","author":"M Murakami","year":"1993","unstructured":"Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993; 260: 1808\u20131810.","journal-title":"Science"},{"key":"BFeye201694_CR43","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1038\/cddis.2013.126","volume":"4","author":"M Leibinger","year":"2013","unstructured":"Leibinger M, M\u00fcller a, Gobrecht P, Diekmann H, Andreadaki a, Fischer D . Interleukin-6 contributes to CNS axon regeneration upon inflammatory stimulation. Cell Death Dis 2013; 4: e609.","journal-title":"Cell Death Dis"},{"key":"BFeye201694_CR44","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1167\/iovs.07-1641","volume":"49","author":"DY Chong","year":"2008","unstructured":"Chong DY, Boehlke CS, Zheng QD, Zhang L, Han Y, Zacks DN . Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci 2008; 49: 3193\u20133200.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J . Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242\u2013248.","journal-title":"Nature"},{"key":"BFeye201694_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","volume":"22","author":"AN Witmer","year":"2003","unstructured":"Witmer AN, GFJM Vrensen, Van Noorden CJF, Schlingemann RO . Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1\u201329.","journal-title":"Prog Retin Eye Res"},{"key":"BFeye201694_CR47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaapos.2005.09.005","volume":"10","author":"MS Brown","year":"2006","unstructured":"Brown MS, Bar\u00f3n AE, France EK, Hamman RF . Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J AAPOS 2006; 10: 143\u2013149.","journal-title":"J AAPOS"},{"key":"BFeye201694_CR48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJMoa041773","volume":"353","author":"D Watanabe","year":"2005","unstructured":"Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782\u2013792.","journal-title":"N Engl J Med"},{"key":"BFeye201694_CR49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1006\/mvre.2002.2426","volume":"64","author":"K Jaquet","year":"2002","unstructured":"Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck K-H . Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64: 326\u2013333.","journal-title":"Microvasc Res"},{"key":"BFeye201694_CR50","first-page":"587","volume":"22","author":"O Pagonopoulou","year":"2008","unstructured":"Pagonopoulou O, Efthimiadou A, Lambropoulou M, Papadopoulos N, Nikolettos NK . Erythropoietin and growth factors exhibit differential angiogenic potential in mouse heart. In Vivo 2008; 22: 587\u2013592.","journal-title":"In Vivo"},{"key":"BFeye201694_CR51","first-page":"451","volume":"27","author":"HF Zhu","year":"2011","unstructured":"Zhu HF, Xu XY, Wan D, Zhang F, Wang HL, Xue LJ . The role of erythropoietin in regulating angiogenesis in brain. Chinese Pharmacol Bull 2011; 27: 451\u2013454.","journal-title":"Chinese Pharmacol Bull"},{"key":"BFeye201694_CR52","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1161\/01.RES.0000260179.43672.fe","volume":"100","author":"M Nakano","year":"2007","unstructured":"Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007; 100: 662\u2013669.","journal-title":"Circ Res"},{"key":"BFeye201694_CR53","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2009-04-216432","volume":"115","author":"L Sautina","year":"2010","unstructured":"Sautina L, Sautin Y, Beem E, Zhou Z, Schuler A, Brennan J et al. Induction of nitric oxide by erythropoietin is mediated by the \u03b2 common receptor and requires interaction with VEGF receptor 2. Blood 2010; 115: 896\u2013905.","journal-title":"Blood"},{"key":"BFeye201694_CR54","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ajpath.2013.12.023","volume":"184","author":"Z Yang","year":"2014","unstructured":"Yang Z, Wang H, Jiang Y, Hartnett ME . VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. Am J Pathol 2014; 184: 1230\u20131239.","journal-title":"Am J Pathol"},{"key":"BFeye201694_CR55","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.2337\/diacare.28.9.2252","volume":"28","author":"Y Katsura","year":"2005","unstructured":"Katsura Y, Okano T, Matsuno K, Osako M, Kure M, Watanabe T et al. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care 2005; 28: 2252\u20132254.","journal-title":"Diabetes Care"},{"key":"BFeye201694_CR56","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1073\/pnas.0800454105","volume":"105","author":"Z Tong","year":"2008","unstructured":"Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 2008; 105: 6998\u20137003.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye201694_CR57","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.2337\/dc06-0556","volume":"29","author":"C Hern\u00e1ndez","year":"2006","unstructured":"Hern\u00e1ndez C, Fonollosa A, Garc\u00eda-Ram\u00edrez M, Higuera M, Catal\u00e1n R, Miralles A et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2006; 29: 2028\u20132033.","journal-title":"Diabetes Care"},{"key":"BFeye201694_CR58","first-page":"151","volume":"17","author":"A Borhani-Haghighi","year":"2012","unstructured":"Borhani-Haghighi A, Ghodsi M, Razeghinejad MR, Mardani S, Mardani M, Nikseresht AR et al. Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event. Neurosciences (Riyadh) 2012; 17: 151\u2013155.","journal-title":"Neurosciences (Riyadh)"},{"key":"BFeye201694_CR59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23573","volume":"72","author":"K-W S\u00fchs","year":"2012","unstructured":"S\u00fchs K-W, Hein K, S\u00e4ttler MB, G\u00f6rlitz A, Ciupka C, Scholz K et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72: 199\u2013210.","journal-title":"Ann Neurol"},{"key":"BFeye201694_CR60","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00417-014-2925-7","volume":"253","author":"V Shayegannejad","year":"2015","unstructured":"Shayegannejad V, Shahzamani S, Dehghani A, Dast Borhan Z, Rahimi M, Mirmohammadsadeghi A . A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin. Graefes Arch Clin Exp Ophthalmol 2015; 253: 797\u2013801.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye201694_CR61","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00417-010-1534-3","volume":"249","author":"MB Kashkouli","year":"2011","unstructured":"Kashkouli MB, Pakdel F, Sanjari MS, Haghighi A, Nojomi M, Homaee MH et al. Erythropoietin: a novel treatment for traumatic optic neuropathy-a pilot study. Graefes Arch Clin Exp Ophthalmol 2011; 249: 731\u2013736.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye201694_CR62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/WNO.0b013e318262a7c2","volume":"32","author":"M Pakravan","year":"2012","unstructured":"Pakravan M, Sanjari N . Erythropoietin treatment for methanol optic neuropathy. J Neuroophthalmol 2012; 32: 325\u2013328.","journal-title":"J Neuroophthalmol"},{"key":"BFeye201694_CR63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3928\/15428877-20091230-03","volume":"41","author":"W Li","year":"2010","unstructured":"Li W, Sinclair SH, Xu G-T . Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging 2010; 41: 18\u201325.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"BFeye201694_CR64","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1167\/iovs.14-14235","volume":"55","author":"SH Sinclair","year":"2014","unstructured":"Sinclair SH, Hurley K, Parvus B, Presti P . Intravitreal Erythropoietin in Eyes with Geographic Atrophy Secondary to Age-related Macular Degeneration. Invest Ophthalmol Vis Sci 2014; 55: 5890\u20135890.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR65","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/bjo.2010.191627","volume":"95","author":"M Modarres","year":"2011","unstructured":"Modarres M, Falavarjani KG, Nazari H, Sanjari MS, Aghamohammadi F, Homaii M et al. Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 2011; 95: 992\u2013995.","journal-title":"Br J Ophthalmol"},{"key":"BFeye201694_CR66","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/bjo.2008.156794","volume":"93","author":"WA Lagr\u00e8ze","year":"2009","unstructured":"Lagr\u00e8ze WA, Feltgen N, Bach M, Jehle T . Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol 2009; 93: 1667\u20131671.","journal-title":"Br J Ophthalmol"},{"key":"BFeye201694_CR67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000369885","volume":"53","author":"W Luo","year":"2015","unstructured":"Luo W, Hu L, Wang F . The protective effect of erythropoietin on the retina. Ophthalmic Res 2015; 53: 74\u201381.","journal-title":"Ophthalmic Res"},{"key":"BFeye201694_CR68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/IJG.0b013e318156a556","volume":"16","author":"JC Tsai","year":"2007","unstructured":"Tsai JC, Song BJ, Wu L, Forbes M . Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007; 16: 567\u2013571.","journal-title":"J Glaucoma"},{"key":"BFeye201694_CR69","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1167\/iovs.06-0757","volume":"48","author":"L Zhong","year":"2007","unstructured":"Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT et al. Erythropoietin promotes survival of retinal ganglion cells in DBA\/2J glaucoma mice. Invest Ophthalmol Vis Sci 2007; 48: 1212\u20131218.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR70","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-011-9579-6","volume":"41","author":"C Hern\u00e1ndez","year":"2012","unstructured":"Hern\u00e1ndez C, Sim\u00f3 R . Erythropoietin produced by the retina: Its role in physiology and diabetic retinopathy. Endocrine 2012; 41: 220\u2013226.","journal-title":"Endocrine"},{"key":"BFeye201694_CR71","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/bjo.2007.119404","volume":"91","author":"S Kase","year":"2007","unstructured":"Kase S, Saito W, Ohgami K, Yoshida K, Furudate N, Saito A et al. Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br J Ophthalmol 2007; 91: 1376\u20131378.","journal-title":"Br J Ophthalmol"},{"key":"BFeye201694_CR72","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jdiacomp.2012.05.005","volume":"26","author":"N Mohan","year":"2012","unstructured":"Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V . Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications 2012; 26: 435\u2013441.","journal-title":"J Diabetes Complications"},{"key":"BFeye201694_CR73","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.earlhumdev.2011.01.027","volume":"87","author":"C Romagnoli","year":"2011","unstructured":"Romagnoli C, Tesfagabir MG, Giannantonio C, Papacci P . Erythropoietin and retinopathy of prematurity. Early Hum Dev 2011; 87: S39\u2013S42.","journal-title":"Early Hum Dev"},{"key":"BFeye201694_CR74","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1442-9071.2006.01437.x","volume":"35","author":"JB Jonas","year":"2007","unstructured":"Jonas JB, Neumaier M . Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy. Clin Experiment Ophthalmol 2007; 35: 186\u2013187.","journal-title":"Clin Experiment Ophthalmol"},{"key":"BFeye201694_CR75","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/02713680701531074","volume":"32","author":"Z Xie","year":"2007","unstructured":"Xie Z, Wu X, Qiu Q, Gong Y, Song Y, Gu Q et al. Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment. Curr Eye Res 2007; 32: 757\u2013764.","journal-title":"Curr Eye Res"},{"key":"BFeye201694_CR76","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/15665240113139990071","volume":"13","author":"Y Guan","year":"2013","unstructured":"Guan Y, Cui L, Qu Z, Lu L, Wang F, Wu Y et al. Subretinal transplantation of rat MSCs and erythropoietin gene modified rat MSCs for protecting and rescuing degenerative retina in rats. Curr Mol Med 2013; 13: 1419\u20131431.","journal-title":"Curr Mol Med"},{"key":"BFeye201694_CR77","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00417-013-2367-7","volume":"251","author":"AP Resende","year":"2013","unstructured":"Resende AP, S\u00e3o-Braz B, Delgado E . Alternative route for erythropoietin ocular administration. Graefes Arch Clin Exp Ophthalmol 2013; 251: 2051\u20132056.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye201694_CR78","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/jop.2008.0021","volume":"24","author":"Y-S Zhong","year":"2008","unstructured":"Zhong Y-S, Liu X-H, Cheng Y, Min Y-J . Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. J Ocul Pharmacol Ther 2008; 24: 453\u2013459.","journal-title":"J Ocul Pharmacol Ther"},{"key":"BFeye201694_CR79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000351627","volume":"50","author":"E Livny","year":"2013","unstructured":"Livny E, Livnat T, Yakimov M, Masoud M, Weinberger D, Bahar I . Effect of erythropoietin on healing of corneal epithelial defects in rabbits. Ophthalmic Res 2013; 50: 129\u2013133.","journal-title":"Ophthalmic Res"},{"key":"BFeye201694_CR80","first-page":"459","volume":"106","author":"JC Tsai","year":"2008","unstructured":"Tsai JC . Safety of intravitreally administered recombinant erythropoietin (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106: 459\u2013472.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"BFeye201694_CR81","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1080\/02713680802366602","volume":"33","author":"BJ Song","year":"2008","unstructured":"Song BJ, Cai H, Tsai JC, Chang S, Forbes M, Del Priore L V . Intravitreal recombinant human erythropoietin: a safety study in rabbits. Curr Eye Res 2008; 33: 750\u2013760.","journal-title":"Curr Eye Res"},{"key":"BFeye201694_CR82","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1073\/pnas.1031753100","volume":"100","author":"S Erbayraktar","year":"2003","unstructured":"Erbayraktar S, Grasso G, Sfacteria A, Xie Q, Coleman T, Kreilgaard M et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100: 6741\u20136746.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye201694_CR83","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3171\/spi.2006.4.4.310","volume":"4","author":"G Grasso","year":"2006","unstructured":"Grasso G, Sfacteria A, Erbayraktar S, Passalacqua M, Meli F, Gokmen N et al. Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine 2006; 4: 310\u2013318.","journal-title":"J Neurosurg Spine"},{"key":"BFeye201694_CR84","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1471-4159.2004.02769.x","volume":"91","author":"X Wang","year":"2004","unstructured":"Wang X, Zhu C, Wang X, Gerwien JG, Schrattenholz A, Sandberg M et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004; 91: 900\u2013910.","journal-title":"J Neurochem"},{"key":"BFeye201694_CR85","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","volume":"97","author":"ML Brines","year":"2000","unstructured":"Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526\u201310531.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye201694_CR86","first-page":"109","volume":"15","author":"ST Provatopoulou","year":"2011","unstructured":"Provatopoulou ST, Ziroyiannis PN . Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. Hippokratia 2011; 15: 109\u2013115.","journal-title":"Hippokratia"},{"key":"BFeye201694_CR87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/s-0029-1224872","volume":"27","author":"N Shah","year":"2010","unstructured":"Shah N, Jadav P, Jean-Baptiste D, Weedon J, Cohen LM, Kim MR . The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Am J Perinatol 2010; 27: 67\u201371.","journal-title":"Am J Perinatol"},{"key":"BFeye201694_CR88","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3341\/kjo.2014.28.5.373","volume":"28","author":"Y Gholamhossein","year":"2014","unstructured":"Gholamhossein Y, Behrouz H, Asghar Z . Diabetic Retinopathy Risk Factors: Plasma Erythropoietin as a Risk Factor for Proliferative Diabetic Retinopathy. Korean J Ophthalmol 2014; 28: 373\u2013378.","journal-title":"Korean J Ophthalmol"},{"key":"BFeye201694_CR89","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.yjmcc.2009.09.005","volume":"47","author":"R Ramirez","year":"2009","unstructured":"Ramirez R, Carracedo J, Nogueras S, Buendia P, Merino A, Ca\u00f1adillas S et al. Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis. J Mol Cell Cardiol 2009; 47: 781\u2013788.","journal-title":"J Mol Cell Cardiol"},{"key":"BFeye201694_CR90","doi-asserted-by":"crossref","first-page":"453179","DOI":"10.1155\/2011\/453179","volume":"2011","author":"S Carelli","year":"2011","unstructured":"Carelli S, Marfia G, Di Giulio AM, Ghilardi G, Gorio A . Erythropoietin: Recent developments in the treatment of spinal cord injury. Neurol Res Int 2011; 2011: 453179.","journal-title":"Neurol Res Int"},{"key":"BFeye201694_CR91","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00417-015-2969-3","volume":"253","author":"X Liu","year":"2015","unstructured":"Liu X, Zhu B, Zou H, Hu D, Gu Q, Liu K et al. Carbamylated erythropoietin mediates retinal neuroprotection in streptozotocin-induced early-stage diabetic rats. Graefes Arch Clin Exp Ophthalmol 2015; 253: 1263\u20131272.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye201694_CR92","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","volume":"29","author":"S Boesch","year":"2014","unstructured":"Boesch S, Nachbauer W, Mariotti C, Sacca F, Filla A, Klockgether T et al. Safety and tolerability of carbamylated erythropoietin in Friedreich\u2019s ataxia. Mov Disord 2014; 29: 935\u2013939.","journal-title":"Mov Disord"},{"key":"BFeye201694_CR93","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.brainres.2008.08.017","volume":"1238","author":"PA Lapchak","year":"2008","unstructured":"Lapchak PA, Kirkeby A, Zivin JA, Sager TN . Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. Brain Res 2008; 1238: 208\u2013214.","journal-title":"Brain Res"},{"key":"BFeye201694_CR94","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-62703-308-4_16","volume":"982","author":"P Colella","year":"2013","unstructured":"Colella P, Auricchio A . Photoreceptor degeneration in mice: Adeno-associated viral vector-mediated delivery of erythropoietin. Methods Mol Biol 2013; 982: 237\u2013263.","journal-title":"Methods Mol Biol"},{"issue":"Suppl 1","key":"BFeye201694_CR95","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1681\/ASN.V11suppl_2s159","volume":"11","author":"D Bohl","year":"2000","unstructured":"Bohl D, Heard JM . Delivering erythropoietin through genetically engineered cells. J Am Soc Nephrol 2000; 11 (Suppl 1): S159\u2013S162.","journal-title":"J Am Soc Nephrol"},{"key":"BFeye201694_CR96","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1006\/mthe.2002.0660","volume":"6","author":"A Auricchio","year":"2002","unstructured":"Auricchio A, Rivera VM, Clackson T, O\u2019Connor EE, Maguire AM, Tolentino MJ et al. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 2002; 6: 238\u2013242.","journal-title":"Mol Ther"},{"key":"BFeye201694_CR97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/15665232113139990024","volume":"13","author":"J Hines-Beard","year":"2013","unstructured":"Hines-Beard J, Desai S, Haag R, Esumi N, D\u2019Surney L, Parker S et al. Identification of a therapeutic dose of continuously delivered erythropoietin in the eye using an inducible promoter system. Curr Gene Ther 2013; 13: 275\u2013281.","journal-title":"Curr Gene Ther"},{"key":"BFeye201694_CR98","doi-asserted-by":"crossref","first-page":"10296","DOI":"10.3390\/ijms150610296","volume":"15","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H et al. Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci 2014; 15: 10296\u201310333.","journal-title":"Int J Mol Sci"},{"key":"BFeye201694_CR99","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/cdd.2009.95","volume":"16","author":"L Danielyan","year":"2009","unstructured":"Danielyan L, Sch\u00e4fer R, Schulz A, Ladewig T, Lourhmati A, Buadze M et al. Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin. Cell Death Differ 2009; 16: 1599\u20131614.","journal-title":"Cell Death Differ"},{"key":"BFeye201694_CR100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1345\/aph.1G042","volume":"40","author":"RJ Cersosimo","year":"2006","unstructured":"Cersosimo RJ, Jacobson DR . Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother 2006; 40: 58\u201365.","journal-title":"Ann Pharmacother"},{"key":"BFeye201694_CR101","first-page":"4","volume":"64","author":"E Ostrvica","year":"2010","unstructured":"Ostrvica E, Mesic E, Ostrvica D, Delic J, Delic-Custendil S, Hukic F . Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta. Med Arh 2010; 64: 4\u20136.","journal-title":"Med Arh"},{"key":"BFeye201694_CR102","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1634\/theoncologist.9-4-451","volume":"9","author":"J Patton","year":"2004","unstructured":"Patton J, Reeves T, Wallace J . Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004; 9: 451\u2013458.","journal-title":"Oncologist"},{"key":"BFeye201694_CR103","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.coph.2006.01.003","volume":"6","author":"EJ Sharples","year":"2006","unstructured":"Sharples EJ, Thiemermann C, Yaqoob MM . Novel applications of recombinant erythropoietin. Curr Opin Pharmacol 2006; 6: 184\u2013189.","journal-title":"Curr Opin Pharmacol"},{"key":"BFeye201694_CR104","first-page":"1","volume-title":"Erythropoietin and the Nervous System","author":"L Torup","year":"2006","unstructured":"Torup L, Leist M . Development of non-erythropoietic erythropoietin variants for neuroprotection. In: H\u00f6ke A (ed). Erythropoietin and the Nervous System. Springer US: Boston, MA, USA, 2006. pp 1\u20139."},{"key":"BFeye201694_CR105","first-page":"263","volume":"23","author":"T Rabie","year":"2008","unstructured":"Rabie T, Marti HH . Brain protection by erythropoietin: a manifold task. Physiology (Bethesda) 2008; 23: 263\u2013274.","journal-title":"Physiology (Bethesda)"},{"key":"BFeye201694_CR106","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.drudis.2013.05.011","volume":"18","author":"AA Kaspar","year":"2013","unstructured":"Kaspar AA, Reichert JM . Future directions for peptide therapeutics development. Drug Discov Today 2013; 18: 807\u2013817.","journal-title":"Drug Discov Today"},{"key":"BFeye201694_CR107","first-page":"17","volume":"35","author":"PL Mok","year":"2013","unstructured":"Mok PL, Leong CF, Cheong SK . Cellular mechanisms of emerging applications of mesenchymal stem cells. Malays J Pathol 2013; 35: 17\u201332.","journal-title":"Malays J Pathol"},{"key":"BFeye201694_CR108","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nbt.2643","volume":"31","author":"A Gonzalez-Cordero","year":"2013","unstructured":"Gonzalez-Cordero A, West EL, Pearson R a, Duran Y, Carvalho LS, Chu CJ et al. Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. Nat Biotechnol 2013; 31: 741\u2013747.","journal-title":"Nat Biotechnol"},{"key":"BFeye201694_CR109","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.stem.2009.07.002","volume":"5","author":"M Idelson","year":"2009","unstructured":"Idelson M, Alper R, Obolensky A, Ben-Shushan E, Hemo I, Yachimovich-Cohen N et al. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell 2009; 5: 396\u2013408.","journal-title":"Cell Stem Cell"},{"key":"BFeye201694_CR110","doi-asserted-by":"crossref","first-page":"12769","DOI":"10.1073\/pnas.0601990103","volume":"103","author":"DA Lamba","year":"2006","unstructured":"Lamba DA, Karl MO, Ware CB, Reh TA . Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc Natl Acad Sci USA 2006; 103: 12769\u201312774.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye201694_CR111","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1523\/JNEUROSCI.23-21-07742.2003","volume":"23","author":"A Kicic","year":"2003","unstructured":"Kicic A, Shen W-Y, Wilson AS, Constable IJ, Robertson T, Rakoczy PE . Differentiation of marrow stromal cells into photoreceptors in the rat eye. J Neurosci 2003; 23: 7742\u20137749.","journal-title":"J Neurosci"},{"key":"BFeye201694_CR112","first-page":"444","volume":"48","author":"YX Tao","year":"2010","unstructured":"Tao YX, Xu HW, Yin ZQ, Fitzgibbon T . Noggin induces human bone marrow-derived mesenchymal stem cells to differentiate into neural and photoreceptor cells. Indian J Exp Biol 2010; 48: 444\u2013452.","journal-title":"Indian J Exp Biol"},{"key":"BFeye201694_CR113","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1634\/stemcells.20-4-279","volume":"20","author":"M Tomita","year":"2002","unstructured":"Tomita M, Adachi Y, Yamada H, Takahashi K, Kiuchi K, Oyaizu H et al. Bone marrow-derived stem cells can differentiate into retinal cells in injured rat retina. Stem Cells 2002; 20: 279\u2013283.","journal-title":"Stem Cells"},{"key":"BFeye201694_CR114","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1167\/iovs.13-13045","volume":"54","author":"B Mead","year":"2013","unstructured":"Mead B, Logan A, Berry M, Leadbeater W, Scheven Ba . Intravitreally transplanted dental pulp stem cells promote neuroprotection and axon regeneration of retinal ganglion cells after optic nerve injury. Invest Ophthalmol Vis Sci 2013; 54: 7544\u20137556.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR115","doi-asserted-by":"crossref","first-page":"e109305","DOI":"10.1371\/journal.pone.0109305","volume":"9","author":"B Mead","year":"2014","unstructured":"Mead B, Logan A, Berry M, Leadbeater W, Scheven BA . Paracrine-mediated neuroprotection and neuritogenesis of axotomised retinal ganglion cells by human dental pulp stem cells: Comparison with human bone marrow and adipose-derived mesenchymal stem cells. PLoS One 2014; 9: e109305.","journal-title":"PLoS One"},{"key":"BFeye201694_CR116","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1590\/S0004-27492008000500007","volume":"71","author":"P Castanheira","year":"2008","unstructured":"Castanheira P, Torquetti L, Nehemy MB, Goes AM . Retinal incorporation and differentiation of mesenchymal stem cells intravitreally injected in the injured retina of rats. Arq Bras Oftalmol 2008; 71: 644\u2013650.","journal-title":"Arq Bras Oftalmol"},{"key":"BFeye201694_CR117","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/stem.1037","volume":"30","author":"CB Mellough","year":"2012","unstructured":"Mellough CB, Sernagor E, Moreno-Gimeno I, Steel DHW, Lako M . Efficient stage-specific differentiation of human pluripotent stem cells toward retinal photoreceptor cells. Stem Cells 2012; 30: 673\u2013686.","journal-title":"Stem Cells"},{"key":"BFeye201694_CR118","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nprot.2009.51","volume":"4","author":"F Osakada","year":"2009","unstructured":"Osakada F, Ikeda H, Sasai Y, Takahashi M . Stepwise differentiation of pluripotent stem cells into retinal cells. Nat Protoc 2009; 4: 811\u2013824.","journal-title":"Nat Protoc"},{"key":"BFeye201694_CR119","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1167\/iovs.04-0511","volume":"45","author":"HJ Klassen","year":"2004","unstructured":"Klassen HJ, Ng TF, Kurimoto Y, Kirov I, Shatos M, Coffey P et al. Multipotent retinal progenitors express developmental markers, differentiate into retinal neurons, and preserve light-mediated behavior. Invest Ophthalmol Vis Sci 2004; 45: 4167\u20134173.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR120","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.exer.2004.11.001","volume":"80","author":"G Qiu","year":"2005","unstructured":"Qiu G, Seiler MJ, Mui C, Arai S, Aramant RB, De Juan E et al. Photoreceptor differentiation and integration of retinal progenitor cells transplanted into transgenic rats. Exp Eye Res 2005; 80: 515\u2013525.","journal-title":"Exp Eye Res"},{"key":"BFeye201694_CR121","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5966\/sctm.2012-0163","volume":"2","author":"DE Buchholz","year":"2013","unstructured":"Buchholz DE, Pennington BO, Croze RH, Hinman CR, Coffey PJ, Clegg DO . Rapid and efficient directed differentiation of human pluripotent stem cells into retinal pigmented epithelium. Stem Cells Transl Med 2013; 2: 384\u2013393.","journal-title":"Stem Cells Transl Med"},{"key":"BFeye201694_CR122","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14653240802714819","volume":"11","author":"U Vossmerbaeumer","year":"2009","unstructured":"Vossmerbaeumer U, Ohnesorge S, Kuehl S, Haapalahti M, Kluter H, Jonas JB et al. Retinal pigment epithelial phenotype induced in human adipose tissue-derived mesenchymal stromal cells. Cytotherapy 2009; 11: 177\u2013188.","journal-title":"Cytotherapy"},{"key":"BFeye201694_CR123","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/mt.2010.144","volume":"18","author":"H-Y Hou","year":"2010","unstructured":"Hou H-Y, Liang H-L, Wang Y-S, Zhang Z-X, Wang B-R, Shi Y-Y et al. A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions. Mol Ther 2010; 18: 1837\u20131845.","journal-title":"Mol Ther"},{"key":"BFeye201694_CR124","doi-asserted-by":"crossref","first-page":"e102013","DOI":"10.1371\/journal.pone.0102013","volume":"9","author":"S Busch","year":"2014","unstructured":"Busch S, Kannt A, Kolibabka M, Schlotterer A, Wang Q, Lin J et al. Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegeneration. PLoS One 2014; 9: e102013.","journal-title":"PLoS One"},{"key":"BFeye201694_CR125","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.yexcr.2013.04.008","volume":"319","author":"N Liu","year":"2013","unstructured":"Liu N, Tian J, Cheng J, Zhang J . Effect of erythropoietin on the migration of bone marrow-derived mesenchymal stem cells to the acute kidney injury microenvironment. Exp Cell Res 2013; 319: 2019\u20132027.","journal-title":"Exp Cell Res"},{"key":"BFeye201694_CR126","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1073\/pnas.221364198","volume":"98","author":"D Vollrath","year":"2001","unstructured":"Vollrath D, Feng W, Duncan JL, Yasumura D, D\u2019Cruz PM, Chappelow a et al. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci USA 2001; 98: 12584\u201312589.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFeye201694_CR127","doi-asserted-by":"crossref","unstructured":"Tomita H, Sugano E, Isago H, Murayama N, Tamai M . Gene therapy for retinitis pigmentosa. InTech: Martin F (ed). Gene Therapy - Tools and Potential Applications. Vol 127 2013, pp 1\u201321.","DOI":"10.5772\/52987"},{"key":"BFeye201694_CR128","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/mt.2011.162","volume":"19","author":"N Eliopoulos","year":"2011","unstructured":"Eliopoulos N, Zhao J, Forner K, Birman E, Young YK, Bouchentouf M . Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice. Mol Ther 2011; 19: 2072\u20132083.","journal-title":"Mol Ther"},{"key":"BFeye201694_CR129","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1167\/iovs.03-1108","volume":"45","author":"S Arnhold","year":"2004","unstructured":"Arnhold S, Klein H, Semkova I, Addicks K, Schraermeyer U . Neurally selected embryonic stem cells induce tumor formation after long-term survival following engraftment into the subretinal space. Invest Ophthalmol Vis Sci 2004; 45: 4251\u20134255.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR130","doi-asserted-by":"crossref","first-page":"e0128973","DOI":"10.1371\/journal.pone.0128973","volume":"10","author":"SN Leow","year":"2015","unstructured":"Leow SN, Luu CD, Nizam MHH, Mok PL, Ruhaslizan R, Wong HS et al. Safety and efficacy of human Wharton\u2019s Jelly-derived mesenchymal stem cells therapy for retinal degeneration. PLoS One 2015; 10: e0128973.","journal-title":"PLoS One"},{"key":"BFeye201694_CR131","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1634\/stemcells.2006-0308erratum","volume":"25","author":"RD Lund","year":"2007","unstructured":"Lund RD, Wang S, Lu B, Girman S, Holmes T, Sauv\u00e9 Y et al. Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells 2007; 25: 602\u2013611.","journal-title":"Stem Cells"},{"key":"BFeye201694_CR132","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10616-011-9413-2","volume":"64","author":"PL Mok","year":"2012","unstructured":"Mok PL, Cheong SK, Leong CF, Chua KH, Ainoon O . Extended and stable gene expression via nucleofection of MIDGE construct into adult human marrow mesenchymal stromal cells. Cytotechnology 2012; 64: 203\u2013216.","journal-title":"Cytotechnology"},{"key":"BFeye201694_CR133","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1167\/iovs.14-14643","volume":"55","author":"SK Chauhan","year":"2014","unstructured":"Chauhan SK . Mesenchymal stem cells home to inflamed ocular surface and suppress allosensitization in corneal transplantation. Invest Ophthalmol Vis Sci 2014; 55: 6631\u20136638.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201694_CR134","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.3390\/ijms15069372","volume":"15","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Zhang Y, Zhang L, Wang M, Zhang X, Li X . Therapeutic effect of bone marrow mesenchymal stem cells on laser-induced retinal injury in mice. Int J Mol Sci 2014; 15: 9372\u20139385.","journal-title":"Int J Mol Sci"},{"key":"BFeye201694_CR135","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.gt.3301727","volume":"9","author":"A Daga","year":"2002","unstructured":"Daga A, Muraglia A, Quarto R, Cancedda R, Corte G . Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD\/SCID mice. Gene Ther 2002; 9: 915\u2013921.","journal-title":"Gene Ther"},{"key":"BFeye201694_CR136","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tice.2012.04.002","volume":"44","author":"PL Mok","year":"2012","unstructured":"Mok PL, Cheong SK, Leong CF, Chua KH, Ainoon O . Human mesenchymal stromal cells could deliver erythropoietin and migrate to the basal layer of hair shaft when subcutaneously implanted in a murine model. Tissue Cell 2012; 44: 249\u2013256.","journal-title":"Tissue Cell"},{"key":"BFeye201694_CR137","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/14653240701816996","volume":"10","author":"P-L Mok","year":"2008","unstructured":"Mok P-L, Cheong S-K, Leong C-F, Othman A . In vitro expression of erythropoietin by transfected human mesenchymal stromal cells. Cytotherapy 2008; 10: 116\u2013124.","journal-title":"Cytotherapy"},{"key":"BFeye201694_CR138","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.brainres.2005.05.037","volume":"1050","author":"M Yamasaki","year":"2005","unstructured":"Yamasaki M, Mishima HK, Yamashita H, Kashiwagi K, Murata K, Minamoto A et al. Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells. Brain Res 2005; 1050: 15\u201326.","journal-title":"Brain Res"},{"key":"BFeye201694_CR139","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.expneurol.2007.01.017","volume":"205","author":"CE King","year":"2007","unstructured":"King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD . Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol 2007; 205: 48\u201355.","journal-title":"Exp Neurol"},{"key":"BFeye201694_CR140","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.mcn.2005.04.009","volume":"29","author":"A Kretz","year":"2005","unstructured":"Kretz A, Happold CJ, Marticke JK, Isenmann S . Erythropoietin promotes regeneration of adult CNS neurons via Jak2\/Stat3 and PI3K\/AKT pathway activation. Mol Cell Neurosci 2005; 29: 569\u2013579.","journal-title":"Mol Cell Neurosci"},{"key":"BFeye201694_CR141","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.2337\/db11-0026","volume":"60","author":"CM McVicar","year":"2011","unstructured":"McVicar CM, Hamilton R, Colhoun LM, Gardiner TA, Brines M, Cerami A et al. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes 2011; 60: 2995\u20133005.","journal-title":"Diabetes"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye201694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye201694","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye201694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T20:59:11Z","timestamp":1692392351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye201694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,10]]},"references-count":141,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFeye201694"],"URL":"https:\/\/doi.org\/10.1038\/eye.2016.94","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,10]]},"assertion":[{"value":"7 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}